These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 39317850)
1. Pharmacokinetics, Safety, and Immunogenicity of a Biosimilar of Nivolumab (LY01015): A Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Trial in Healthy Chinese Male Subjects. Wang W; Zhang S; Dou C; Hu B; Song H; Qi F; Zhao Y; Li X; Zhou M; Xie J; Deng K; Wu Q; Ye L; Cui C; Liu L; Huang J; Yang G BioDrugs; 2024 Nov; 38(6):855-865. PubMed ID: 39317850 [TBL] [Abstract][Full Text] [Related]
2. A Randomized, Double-Blind, Parallel-Group Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of CMAB015, a Candidate Secukinumab Biosimilar, with Its Reference Product Cosentyx Yao F; Wang C; Ding J; Zhang Q; Zheng L; Zhang Q; Yang T; Zhang X; Shan Y; Hou S; Wang H; Zhou R; Hu W Drug Des Devel Ther; 2024; 18():3891-3901. PubMed ID: 39224901 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics, pharmacodynamics, safety and immunogenicity of recombinant, fully human anti-RANKL monoclonal antibody (MW031) versus denosumab in Chinese healthy subjects: a single-center, randomized, double-blind, single-dose, parallel-controlled trial. Guo Y; Guo T; Di Y; Xu W; Hu Z; Xiao Y; Yu H; Hou J Expert Opin Biol Ther; 2023; 23(8):705-715. PubMed ID: 36892190 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics, safety, and immunogenicity of HLX03, an adalimumab biosimilar, compared with reference biologic in healthy Chinese male volunteers: Results of a randomized, double-blind, parallel-controlled, phase 1 study. Zhang H; Wu M; Sun J; Zhu X; Li C; Ding Y; Zhang X; Chai K; Li X Pharmacol Res Perspect; 2021 Apr; 9(2):e00733. PubMed ID: 33682358 [TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599 [TBL] [Abstract][Full Text] [Related]
6. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017 [TBL] [Abstract][Full Text] [Related]
7. A phase 1 randomized study compare the pharmacokinetics, safety and immunogenicity of HLX04 to reference bevacizumab sourced from the United States, the European Union, and China in healthy Chinese male volunteers. Zhu X; Qian H; Sun J; Wu M; Yu C; Ding Y; Zhang X; Chai K; Li X Cancer Chemother Pharmacol; 2021 Sep; 88(3):465-474. PubMed ID: 34086067 [TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic similarity study comparing the biosimilar candidate, LY05008, with its reference product dulaglutide in healthy Chinese male subjects. Zhang Q; Sun C; Wu J; Wu J; Zhang X; Liu Y; Dou C; Qin H; Zhang Q; Zhou R; Hu W Expert Opin Biol Ther; 2023; 23(8):727-735. PubMed ID: 36880118 [TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics and safety of candidate tocilizumab biosimilar CT-P47 versus reference tocilizumab: a randomized, double-blind, single-dose phase I study. Yu KS; Kim B; Shin D; Park MK; Hwang JG; Kim MG; Chung H; Ghim J; Chung JY; Smolen JS; Burmester GR; Kim S; Bae Y; Jeon D; Yoo J; Yang G; Bae J; Keystone E Expert Opin Investig Drugs; 2023 May; 32(5):429-439. PubMed ID: 37231670 [TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, single-dose study to evaluate the biosimilarity of QL1101 with bevacizumab in healthy male subjects. Liu YN; Huang J; Guo C; Yang S; Ye L; Wu ST; Zhang XF; Yang XY; Han CC; Pei Q; Huang L; He QN; Yang GP Cancer Chemother Pharmacol; 2020 Mar; 85(3):555-562. PubMed ID: 31907645 [TBL] [Abstract][Full Text] [Related]
11. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166 [TBL] [Abstract][Full Text] [Related]
12. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects. Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787 [TBL] [Abstract][Full Text] [Related]
13. A randomized phase I clinical trial comparing the pharmacokinetic, safety, and immunogenicity of potential biosimilar recombinant human HER2 monoclonal antibody for injection and trastuzumab in healthy Chinese adults. Wang J; Niu S; Dong W; Wei L; Ou L; Zhang T; Zhang L; Nie X; Wang Q; Shen T; Wang Q; Xia L; Liu G; Jin J; Zheng Q; Song H; Fang Y Expert Opin Investig Drugs; 2020 Jul; 29(7):755-762. PubMed ID: 32594779 [TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. Singh I; Patel R; Patel A; Jose V Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073 [TBL] [Abstract][Full Text] [Related]
15. A Phase I, Randomized, Double-Blind, Single-Dose, Parallel-Group Study to compare Pharmacokinetic Similarity, Safety, and Immunogenicity Between BAT2506 and Golimumab in Healthy Chinese Male Subjects. Wu M; Sun J; Wu D; Xu J; Wei J; Wang Z; Yu J; Li S; Zhang H; Ding Y Expert Opin Investig Drugs; 2021 Jan; 30(1):77-83. PubMed ID: 33241960 [No Abstract] [Full Text] [Related]
16. Safety and pharmacokinetics of a biosimilar of denosumab (KN012): Phase 1 and bioequivalence study in healthy Chinese subjects. Zhang H; Li C; Liu J; Wu M; Li X; Zhu X; Li Q; Wang B; Mao Y; Ding Y; Jin Q Expert Opin Investig Drugs; 2021 Feb; 30(2):185-192. PubMed ID: 33306418 [TBL] [Abstract][Full Text] [Related]
17. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022 [TBL] [Abstract][Full Text] [Related]
18. A randomized, double-blind, single-dose, phase 1 study comparing the pharmacokinetics, pharmacodynamics, safety, and immunogenicity of denosumab biosimilar CT‑P41 and reference denosumab in healthy males. Kim A; Hong JH; Shin W; Yoo H; Jung JG; Reginster JY; Kim S; Bae Y; Suh J; Kim S; Lee E; Silverman S Expert Opin Biol Ther; 2024 Jul; 24(7):655-663. PubMed ID: 38349618 [TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics of a proposed tocilizumab biosimilar (MSB11456) versus US-licensed tocilizumab: results of a randomized, double-blind, single-intravenous dose study in healthy adults. Tomaszewska-Kiecana M; Ullmann M; Petit-Frere C; Monnet J; Dagres C; Illes A Expert Rev Clin Immunol; 2023 Apr; 19(4):439-446. PubMed ID: 36715299 [TBL] [Abstract][Full Text] [Related]
20. A randomized Phase I pharmacokinetic trial comparing the potential biosimilar trastuzumab (SIBP-01) with the reference product (Herceptin®) in healthy Chinese male volunteers. Zhou H; Cao S; Zhu X; Xie J; Fan L; Ge Q; Wang Y; Zhu J; Liu Y; Shao Z; Shan R; Liu B; Wang H; Ding L Expert Opin Drug Metab Toxicol; 2020 Oct; 16(10):997-1003. PubMed ID: 32847423 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]